Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RDC5 PK in Healthy Volunteers
NCT02016742Phase 1Completed
- Sponsor
- Chronos Therapeutics
- Start
- Dec 2013
- Primary completion
- Feb 2014
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tacrolimus in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Chronos Therapeutics. Primary endpoint: Area under the concentration-time curve from time 0 to infinity. Started Dec 2013; status: completed.
02
Drugs
tacrolimus
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02016742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02016742.